Precision Genetic Medicine Platform Offers New Hope in Cancer Treatment
July 7th, 2025 2:05 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. is pioneering a novel approach to cancer treatment with its precision genetic medicine platform, targeting both primary tumors and metastatic sites, potentially transforming cancer care and addressing other unmet medical needs.
An estimated 20 million people are diagnosed with cancer annually, a number expected to rise to 35 million by 2050, highlighting the urgent need for innovative treatments. Calidi Biotherapeutics Inc. (NYSE American: CLDI) is at the forefront of this challenge, developing a precision genetic medicine platform designed to target and treat cancer more effectively. This platform utilizes engineered viruses to deliver genetic medicines directly to tumors, including metastatic sites, offering a promising new direction in cancer therapy.
The potential of Calidi's technology extends beyond cancer, with preliminary assessments exploring its application in autoimmune diseases and other areas of significant unmet medical need. This positions Calidi alongside leading companies in the genetic medicine and oncology sectors, such as Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), CG Oncology Inc. (NASDAQ: CGON), and Roche (OTCQX: RHHBY), in the quest to revolutionize treatment paradigms.
The development of this platform represents a critical step forward in the fight against cancer, offering hope for more effective treatments and improved patient outcomes. As the global burden of cancer continues to grow, innovations like Calidi's precision genetic medicine platform are essential in addressing the challenges of modern oncology and beyond.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
